综述:肝硬化心肌病的综合分析
该综述系统检索了截至2020年8月的文献,全面分析肝硬化心肌病的定义、病理机制、诊断标准、患病率、管理及对肝移植的影响。新诊断标准基于超声心动图的收缩和舒张功能障碍参数,患病率报告为26%-81%,尚无明确有效的药物治疗,该病增加肝移植术后心血管不良事件风险。
要点
- 新诊断标准基于超声心动图收缩和舒张功能障碍参数。
- 肝硬化患者中患病率报告为26%-81%。
- 尚无明确证据有效的药物治疗,增加肝移植术后心血管风险。
核心结论
- 肝硬化心肌病是影响肝硬化患者发病率和死亡率的临床相关综合征。
研究设计与样本
- 综述类文章,电子检索EMBASE、MEDLINE、EBM Reviews-Cochrane Central Register of Controlled Trials、EBM Reviews-Cochrane Database of Systematic Reviews和Google Scholar数据库,检索截至2020年8月。
主要发现
- 肝硬化心肌病患病率报告为26%-81%。
- 病理机制可能与肝硬化的炎症表型相关。
- 多种药物治疗曾被提出,但均无明确疗效证据。
- 肝硬化心肌病使肝移植过程复杂化,增加移植后心血管不良事件风险。
- 移植后综合征完全逆转仍有争议,但多数研究提示至少术后第一年内未发生逆转。
关键数值与推荐
- 新诊断标准由超声心动图评估的收缩和舒张功能障碍参数组成。
- 心电图异常和生物标志物在定义标准中的作用尚不明确。
临床怎么用
- 临床应关注肝硬化患者的心肌病评估,使用超声心动图参数进行诊断。
- 肝移植评估中需考虑肝硬化心肌病对术后心血管事件风险的影响。
局限性
- 心电图异常和生物标志物在诊断标准中的作用尚不明确。
- 药物治疗缺乏明确疗效证据。
- 移植后完全逆转性仍有争议。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with cirrhosis are at risk of developing cirrhotic cardiomyopathy. This syndrome is unique to cirrhosis and is generally defined as subnormal cardiac function in the absence of prior heart disease. There is no systematic or comprehensive review of cirrhotic cardiomyopathy to date. AIMS: To comprehensively review the literature on the definition, pathogenic mechanisms, diagnostic criteria, prevalence, management and influence on liver transplantation including reversibility of cirrhotic cardiomyopathy. METHODS: Electronic searches of the EMBASE, MEDLINE, EBM Reviews-Cochrane Central Register of Controlled Trials, EBM Reviews-Cochrane Database of Systematic Reviews and Google Scholar databases were conducted. MeSH terms focused on cirrhosis, cardiomyopathy, medication classes and epidemiology. Literature up to August 2020 was reviewed. RESULTS: New diagnostic criteria for the definition of cirrhotic cardiomyopathy have recently been published, consisting of systolic and diastolic dysfunction parameters as assessed by echocardiographic methods. The roles of electrocardiographic disturbances and biomarkers in the definition criteria remain unclear. Pathogenic mechanisms underlying cirrhotic cardiomyopathy are likely related to the inflammatory phenotype of cirrhosis. Prevalence rates of 26%-81% in cirrhotic patients are reported. Several medical therapies have been proposed, but none with clear evidence of efficacy. The presence of cirrhotic cardiomyopathy complicates the liver transplantation process with a higher risk of adverse cardiovascular events post-transplant. Complete reversibility of the syndrome after transplantation remains controversial but most studies suggest that it does not occur at least within the first post-operative year. CONCLUSIONS: Cirrhotic cardiomyopathy is a clinically relevant syndrome that affects morbidity and mortality in patients with cirrhosis.
引用
- Chahal D, Liu H, Shamatutu C, et al. Review article: comprehensive analysis of cirrhotic cardiomyopathy. Aliment Pharmacol Ther. 2021. PMID: 33689169. doi:10.1111/apt.16305
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。